Puretech Health (LON:PRTC)‘s stock had its “buy” rating reiterated by stock analysts at Liberum Capital in a research report issued to clients and investors on Friday. They currently have a GBX 248 ($3.36) price objective on the stock. Liberum Capital’s target price indicates a potential upside of 35.89% from the company’s previous close.
Other equities research analysts have also issued reports about the company. Peel Hunt reiterated a “buy” rating and set a GBX 302 ($4.10) price target on shares of Puretech Health in a report on Tuesday, January 2nd. Numis Securities lifted their price target on Puretech Health from GBX 207 ($2.81) to GBX 233 ($3.16) and gave the company a “buy” rating in a report on Thursday, November 30th. N+1 Singer reiterated a “buy” rating on shares of Puretech Health in a report on Thursday, November 30th. Finally, Jefferies Group reiterated a “buy” rating on shares of Puretech Health in a report on Friday, November 17th. Five analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of GBX 255 ($3.46).
Shares of Puretech Health (LON PRTC) traded up GBX 3 ($0.04) during midday trading on Friday, reaching GBX 182.50 ($2.47). The company’s stock had a trading volume of 109,465 shares, compared to its average volume of 78,873. Puretech Health has a 12-month low of GBX 110 ($1.49) and a 12-month high of GBX 183 ($2.48). The firm has a market cap of $442.41 and a price-to-earnings ratio of -1,013.89.
About Puretech Health
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.